Evidence map›Paper›PMID 42347888›Full record

Trial reportWorld journal of urology2026

Bladder drainage using the coreflow prostatic stent after REZUM therapy.

Thibaut Long-Depaquit, Frederica Sordelli, Anne Laure Charvet, Christopher Agüero, Silvia Secco, Clément Sarrazin, Michael Baboudjian, Marc Fourmarier

Abstract readClinical TrialMulticenter Study
PubMed Publisher
In one paragraph

Trial report in World journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Thibaut Long-DepaquitDepartment of Urology, Hôpital d'Instruction des Armées Sainte-Anne, Toulon, France. Thibaut.long2@gmail.com.
Frederica SordelliDepartment of Urology, Hôpital Nord, Assistance Publique-Hôpitaux de Marseille (AP-HM), Marseille, France.
Anne Laure CharvetDepartment of Urology, Hôpital Nord, Assistance Publique-Hôpitaux de Marseille (AP-HM), Marseille, France.
Christopher AgüeroDepartment of Urology, Hôpital d'Instruction des Armées Sainte-Anne, Toulon, France.
Silvia SeccoDepartment of Urology, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
Clément SarrazinDepartment of Urology, CHU Grenoble Alpes, Université Grenoble Alpes, Grenoble, France.
Michael BaboudjianDepartment of Urology, Hôpital Nord, Assistance Publique-Hôpitaux de Marseille (AP-HM), Marseille, France.
Marc FourmarierDepartment of Urology, Centre Hospitalier du Pays d'Aix, Aix-en-Provence, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo evaluate the feasibility and short-term outcomes of postoperative bladder drainage using a temporary prostatic urethral stent following Rezūm™ therapy.

methodsThis prospective bicentric pilot study included 32 consecutive patients undergoing Rezūm™ therapy between March 2025 and February 2026. Postoperative bladder drainage was performed using a temporary prostatic stent (CoreFlow™, ProstaLund AB, Sweden). The primary endpoint was overall strategy success, defined as successful device insertion, maintenance until planned removal without conversion to standard urethral catheterisation, and no secondary re-catheterisation.

resultsOverall strategy success was achieved in 26 of 32 patients (81%). CoreFlow™ stent insertion was successful in 29 patients (91%). Median duration of stenting was 4 days (IQR 4-6). At 30 days after device removal, median patient satisfaction was 8 (IQR 7-9), and median discomfort score was 2 (IQR 1-2). Macroscopic haematuria occurred in 15 patients (47%), urinary retention in 3 (9%), and urinary tract infection in 1 (3%). No device migration or unplanned hospitalisation was observed.

conclusionTemporary prostatic stenting appears to be a feasible and well-tolerated postoperative drainage strategy following Rezūm™ therapy. Larger comparative studies are needed to determine its clinical benefit.

Indexed as

DrainageProstatic HyperplasiaStentsAgedFeasibility StudiesHumansMaleMiddle AgedPilot ProjectsProspective StudiesTreatment OutcomeBenign prostatic hyperplasiaMinimally invasive surgical therapyRezūmUrinary drainageWater vapor thermal therapy

Identifiers

PMID42347888

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.